Back to top
more

Renaissance IPO ETF: (IPO)

(Delayed Data from NYSE) As of Mar 24, 2023 03:59 PM ET

$27.57 USD

27.57
14,705

-0.19 (-0.68%)

Volume: 14,705

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

NA

After-Market: $27.44 -0.13 (-0.47 %) 7:58 PM ET

ETF Quote Details

Previous Close 27.76
Open 27.57
Bid 27.50
Ask 28.35
Day Low-High 27.26-27.63
52wk Low-High 23.62-46.76
Volume 14,705
NAV (month end) 28.02
Premium (+)/Discount (-) (month end)-0.26

Zacks Premium Research for IPO

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

 NA
ETF Risk

Zacks proprietary quantitative models divide each set of ETFs following a similar investment strategy (style box/industry/asset class) into three risk categories- High, Medium, and Low. The aim of our models is to select the best ETFs within each risk category, so that investors can pick an ETF that matches their particular risk preference in order to better achieve their investment goals.

Med
ETF Snapshot

ETF Expense Ratio

Expense Ratio 0.60%
Dividend (Yield) $0.00 (0.00%)
Issuer RENAISSANCE CAPITAL

Benchmark for IPO

RENAISSANCE IPO INDEX

The Renaissance IPO Index is a portfolio of newly U.S.-listed initial public offerings of companies whose unseasoned equities are under-represented in core U.S. equity indices. IPOs that meet liquidity & operational screens are included in the Index at the end of the fifth day of trading, or upon quarterly reviews, weighted by tradable float, capped at 10% & removed after two years.

Fund Summary for IPO

RENAISSANCE IPO ETF

The Renaissance IPO ETF is designed to provide investors with efficient exposure to a portfolio of newly public companies prior to their inclusion in core U.S. equity portfolios.